The present invention relates to novel stem cell therapeutics and, more specifically, provides cell therapeutics, which comprises a mesenchymal stem cell in which ascorbic acid 2-glucoside (AA2G) of 0.1-5.0 mM is treated as an available component. Therefore, the cell therapeutics is used for treatment of asthma, degenerative arthritis, rheumatic disease, neurological damage, amyotrophic lateral sclerosis, a stroke, Alzheimer&prime；s disease, Parkinson&prime；s disease, Huntington&prime；s disease, osteoporosis, or macular degeneration.COPYRIGHT KIPO 2018본 발명은 신규 줄기세포 치료제에 관한 것으로서, 보다 구체적으로는 0.1 내지 5.0 mM의 아스코르브산 2-글루코사이드(ascorbic acid 2-glucoside, AA2G)가 처리된 중간엽 줄기세포를 유효성분으로 포함하는 천식, 퇴행성 관절염, 류마티스성 질환, 신경손상, 근위축성축삭경화증, 뇌졸중, 알츠하이머병, 파킨슨병, 헌팅턴병, 골다공증, 또는 황반변성의 치료에 사용되는, 세포치료제를 제공한다.
